These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11257352)

  • 1. The prevention of Lyme disease with vaccine.
    Poland GA; Jacobson RM
    Vaccine; 2001 Mar; 19(17-19):2303-8. PubMed ID: 11257352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.
    Onrust SV; Goa KL
    Drugs; 2000 Feb; 59(2):281-99. PubMed ID: 10730551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine.
    Schoen RT; Deshefy-Longhi T; Van-Hoecke C; Buscarino C; Fikrig E
    Clin Ther; 2003 Jan; 25(1):210-24. PubMed ID: 12637121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lyme vaccine: a cautionary tale.
    Nigrovic LE; Thompson KM
    Epidemiol Infect; 2007 Jan; 135(1):1-8. PubMed ID: 16893489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
    Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
    Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lyme vaccine: issues and controversies.
    Rahn DW
    Infect Dis Clin North Am; 2001 Mar; 15(1):171-87. PubMed ID: 11301814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
    Beran J; De Clercq N; Dieussaert I; Van Hoecke C
    Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
    Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
    N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
    Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
    Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic infection with Borrelia burgdorferi.
    Steere AC; Sikand VK; Schoen RT; Nowakowski J
    Clin Infect Dis; 2003 Aug; 37(4):528-32. PubMed ID: 12905137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Lyme disease vaccine--a public health perspective.
    Shen AK; Mead PS; Beard CB
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s247-52. PubMed ID: 21217171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines against Lyme disease: What happened and what lessons can we learn?
    Poland GA
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s253-8. PubMed ID: 21217172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
    Feder HM; Beran J; Van Hoecke C; Abraham B; De Clercq N; Buscarino C; Parenti DL
    J Pediatr; 1999 Nov; 135(5):575-9. PubMed ID: 10547245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should speculations about immune-mediated adverse effects of Lyme disease vaccine deter us from giving it?
    Sigal L
    Cleve Clin J Med; 2000 Dec; 67(12):873-4. PubMed ID: 11127980
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.
    Keller D; Koster FT; Marks DH; Hosbach P; Erdile LF; Mays JP
    JAMA; 1994 Jun; 271(22):1764-8. PubMed ID: 8196120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development.
    Badawi A; Shering M; Rahman S; Lindsay LR
    Can J Public Health; 2017 Apr; 108(1):e62-e70. PubMed ID: 28425901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.